

Cover Story
A brief consult with an undergraduate earning a B or above in Statistics 101 might have acquainted Spectrum Pharmaceuticals executives with all the science that would have saved them from a devastating encounter with an FDA advisory committee.
Free
By Matthew Bin Han Ong
In Brief


Trending Stories
- CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot
- The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago
Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.” - Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
- Team USA’s Julie Letai competes in Milan Olympics speed skating event
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care















